MARKET

CLLS

CLLS

Cellectis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.50
+0.86
+4.17%
Pre Market: 21.73 +0.23 +1.07% 08:45 03/01 EST
OPEN
21.62
PREV CLOSE
20.64
HIGH
22.12
LOW
20.12
VOLUME
419
TURNOVER
--
52 WEEK HIGH
34.71
52 WEEK LOW
7.32
MARKET CAP
913.45M
P/E (TTM)
-11.4374
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cellectis to Hold Fourth Quarter 2020 Earnings Call on Friday, March 5, 2021 at 8:00AM EST
NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will repor...
GlobeNewswire · 3d ago
Cellectis, Cytovia Therapeutics Ink Gene-Edited Therapy Pact For Oncology Indications
Benzinga · 02/16 13:55
Cellectis, Cytovia In $760M Partnership To Develop Natural Killer Cells; Stock Pops 9%
Cytovia Therapeutics and Cellectis, a clinical stage cell therapy company announced a $760 million research and development collaboration to develop TALEN gene edited ...
TipRanks.com · 02/16 12:59
Cellectis teams up with Cytovia Therapeutics to develop natural killer cells
Cytovia Therapeutics, a biopharma developing gene-edited Natural Killer ((NK)) and Chimeric Antigen Receptor ((CAR))-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (CLLS) collaborate to develop TALEN gene-edited iPSC NK and
Seekingalpha · 02/16 06:44
Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells
CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced...
GlobeNewswire · 02/16 06:00
Cellectis: Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of votingrights01/31/2...
GlobeNewswire · 02/10 21:30
Cell therapy biotech Vor Biopharma prices upsized IPO at $18/share, trades today
Vor Biopharma (VOR) has priced its initial public offering of ~9.83M shares at $18/share, for gross proceeds of ~$176.9M.The company originally planned to offer 8.8M shares at a price range
Seekingalpha · 02/05 11:58
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20)
Benzinga · 01/21 13:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLLS. Analyze the recent business situations of Cellectis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLLS stock price target is 35.10 with a high estimate of 50.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 146
Institutional Holdings: 17.68M
% Owned: 41.62%
Shares Outstanding: 42.49M
TypeInstitutionsShares
Increased
22
3.54M
New
41
-515.03K
Decreased
24
941.76K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Executive Board/Director
Andre Choulika
Co-Founder/Executive Vice President/Executive Board/Director
David Sourdive
Chief Financial Officer/Executive Board
Eric Dutang
Executive Vice President/Executive Board
Bill Montelth
Chief Human Resource Officer/Executive Vice President
Kyung Nam-Wortman
Executive Vice President/Executive Board
William Montelth
Executive Vice President/Executive Board
Jon Voss
Senior Vice President
Leopold Bertea
Vice President
Francisco Esteva
Senior Vice President
Steve Doares
Chief Scientific Officer/Executive Board
Philippe Duchateau
Chief Compliance Officer/Executive Board
Stephan Reynier
Vice President/Executive Board
Arthur Stril
General Counsel/Executive Board
Marie-Bleuenn Terrier
Non-Executive Independent Director
Laurent Arthaud
Non-Executive Independent Director
Pierre Bastid
Non-Executive Independent Director
Rainer Boehm
Non-Executive Independent Director
Alain Godard
Non-Executive Independent Director
Herve Hoppenot
Non-Executive Independent Director
Annick Schwebig
  • Dividends
  • Splits
  • Insider Activity
No Data
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Webull offers kinds of Cellectis SA (ADR) stock information, including NASDAQ:CLLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLLS stock methods without spending real money on the virtual paper trading platform.